220 related articles for article (PubMed ID: 18519780)
1. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
[TBL] [Abstract][Full Text] [Related]
2. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
3. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
[TBL] [Abstract][Full Text] [Related]
4. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
[TBL] [Abstract][Full Text] [Related]
6. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
12. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
Shamseddine AI; Khalifeh MJ; Mourad FH; Chehal AA; Al-Kutoubi A; Abbas J; Habbal MZ; Malaeb LA; Bikhazi AB
Clin Pharmacokinet; 2005; 44(9):957-67. PubMed ID: 16122282
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
17. Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients.
Specenier P; Guetens G; Dyck J; De Boeck G; Weyler J; Van den Weyngaert D; Aelbrecht K; Vermorken JB
Cancer Chemother Pharmacol; 2011 Jul; 68(1):185-91. PubMed ID: 20882386
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
[TBL] [Abstract][Full Text] [Related]
19. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.
Stuurman FE; Voest EE; Awada A; Witteveen PO; Bergeland T; Hals PA; Rasch W; Schellens JH; Hendlisz A
Invest New Drugs; 2013 Aug; 31(4):959-66. PubMed ID: 23345000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
